British Columbia Extends Biosimilar Switching To Adalimumab

Follows Launch Of Five Humira Biosimilars In Canada In February

British Columbia has expanded its biosimilar switching program to cover patients being treated with Humira in the Canadian province.

British Columbia Canada Flags
British Columbia is flying the flag for biosimilar switching in Canada • Source: Alamy

Patients being treated with Humira (adalimumab) in British Columbia will soon be switched to adalimumab biosimilars, after the Canadian province expanded its biosimilar switching program to cover the blockbuster biologic.

Almost two years ago, British Columbia launched its biosimilar switching program that saw patients being treated with etanercept, infliximab and...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.